Search results for "SART"

showing 10 items of 212 documents

Dysarthria in acute ischemic stroke: lesion topography, clinicoradiologic correlation, and etiology.

2001

Background and purpose: Although dysarthria is a frequent symptom in cerebral ischemia, there is little information on its anatomic specificity, spectrum of associated clinical characteristics, and etiologic mechanisms. Methods: An investigation of 68 consecutive patients with sudden onset of dysarthria due to a single infarction confirmed by MRI or CT was conducted. Results: Dysarthria was associated with a classic lacunar stroke syndrome in 52.9% of patients. Isolated dysarthria and dysarthria–central facial and lingual paresis occurred in 2.9% (n = 2) and 10.3% (n = 7), respectively. Dysarthria–clumsy hand syndrome was observed in 11.7% (n = 8) of patients and associated with pure motor …

AdultBrain InfarctionMalePathologymedicine.medical_specialtyLacunar strokeInternal capsuleBrain IschemiaDysarthriaInternal Capsulemedicine.arteryInternal medicineCerebellumCentrum semiovalemedicineHumansSuperior cerebellar arteryAgedRetrospective StudiesAged 80 and overChi-Square Distributionbusiness.industryCerebral infarctionCerebral peduncleDysarthriaMiddle Agedmedicine.diseasenervous system diseasesHemiparesisIschemic Attack TransientCardiologyFemaleNeurology (clinical)medicine.symptombusinessNeurology
researchProduct

Executive and arousal vigilance decrement in the context of the attentional networks: The ANTI-Vea task

2018

Vigilance is generally understood as the ability to detect infrequent critical events through long time periods. In tasks like the Sustained Attention to Response Task (SART), participants tend to detect fewer events across time, a phenomenon known as vigilance decrement. However, vigilance might also involve sustaining a tonic arousal level. In the Psychomotor Vigilance Test (PVT), the vigilance decrement corresponds to an increment across time in both mean and variability of reaction time. New Method: The present study aimed to develop a single task Attentional Networks Test for Interactions and Vigilance executive and arousal components (ANTI-Vea) to simultaneously assess both components…

AdultMaleAdolescentmedia_common.quotation_subjectVIGILANCE DECREMENTNeuropsychological TestsPhasic alertnessbehavioral disciplines and activities050105 experimental psychologyArousalCIENCIAS SOCIALESExecutive FunctionYoung Adult03 medical and health sciences0302 clinical medicineSingle taskReaction TimeHumansAttention0501 psychology and cognitive sciencesAROUSAL VIGILANCEmedia_commonPsychomotor learningPSYCHOMOTOR VIGILANCE TEST (PVT)General Neuroscience05 social sciencesOtras PsicologíaResponse biasPsicologíaSUSTAINED ATTENTION TO RESPONSE TASK (SART)EXECUTIVE VIGILANCEFemaleArousalPsychologyPsychomotor Performance030217 neurology & neurosurgeryATTENTIONAL NETWORKS TEST-INTERACTIONS (ANT-I)Cognitive psychologyVigilance (psychology)Journal of Neuroscience Methods
researchProduct

Cerebellar speech representation: lesion topography in dysarthria as derived from cerebellar ischemia and functional magnetic resonance imaging.

2003

Background Lesion topography and the pathophysiological background of dysarthria due to focal cerebellar lesions have not yet been fully clarified. Objectives To investigate the lesion topography of dysarthria due to cerebellar ischemia and evaluate brainstem functions. Design Case studies. Patients Eighteen right-handed patients with sudden-onset dysarthria and cerebellar ischemia with and without brainstem involvement and 19 healthy, right-handed, monolingual, German-speaking volunteers. Methods In patients, we used multimodal electrophysiologic techniques to investigate brainstem functions. Functional magnetic resonance imaging (MRI) was performed in the 19 healthy volunteers. Activation…

AdultMaleCerebellumPathologymedicine.medical_specialtyBrain IschemiaDysarthriaArts and Humanities (miscellaneous)Tonguemedicine.arteryCerebellar hemisphereCerebellumMedicineHumansSpeechSuperior cerebellar arteryLateral medullary syndromeBrain MappingMouthbusiness.industryDysarthriamedicine.diseaseMagnetic Resonance ImagingAnterior inferior cerebellar arteryElectrophysiologyPosterior inferior cerebellar arterymedicine.anatomical_structurenervous systemFemaleNeurology (clinical)Brainstemmedicine.symptombusinessBrain StemArchives of neurology
researchProduct

Rationale for and design of the CREATIVE-AF trial: randomized, double-blind, placebo-controlled, crossover study of the effect of irbesartan on oxida…

2008

Background and objective: Atrial fibrillation (AF) is the most common cardiac arrhythmia. Recent studies suggest there is an angiotensin II-dependent increase in adhesion molecules and oxidative stress parameters during AF. These alterations appear to contribute to inflammatory and prothrombotic changes in the atrial endocardium (‘endocardial remodelling’), suggesting that patients with increased levels of these factors might be at risk of thromboembolic events. The purpose of the CREATIVE-AF (Impact of Irbesartan on Oxidative Stress and C-Reactive Protein Levels in Patients with Persistent Atrial Fibrillation) trial is to prove the principle concept that blockade of angiotensin II type 1 r…

AdultMalemedicine.medical_specialtyAdolescentEndpoint DeterminationTetrazolesmedicine.disease_causeYoung AdultIrbesartanVon Willebrand factorDouble-Blind MethodInternal medicineAtrial FibrillationmedicineHumansPharmacology (medical)Cell adhesionAgedCross-Over StudiesbiologyCell adhesion moleculebusiness.industryPatient SelectionBiphenyl CompoundsAtrial fibrillationGeneral MedicineIrbesartanMiddle Agedmedicine.diseaseAngiotensin IICrossover studyOxidative StressData Interpretation StatisticalSample SizeCardiologybiology.proteinFemalebusinessAngiotensin II Type 1 Receptor BlockersCell Adhesion MoleculesOxidative stressBiomarkersmedicine.drugClinical drug investigation
researchProduct

The effect duration of candesartan cilexetil once daily, in comparison with enalapril once daily, in patients with mild to moderate hypertension.

2001

To determine the antihypertensive efficacy, effect duration and safety of the angiotensin II type 1 receptor blocker candesartan cilexetil and the angiotensin converting enzyme inhibitor enalapril once daily in patients with mild to moderate hypertension.A multicenter, randomised, double-blind parallel group study was performed in Finland, France, the Netherlands, Spain and Sweden. Three-hundred-and-ninety-five men and women in the age range 20-80 years with primary hypertension were randomised to an 8-week double-blind treatment period with either candesartan cilexetil 8-16 mg or enalapril 10-20 mg once daily, with forced dose titration after 4 weeks. Non-invasive ambulatory blood pressure…

AdultMalemedicine.medical_specialtyAmbulatory blood pressureTime Factorsmedicine.medical_treatmentDiastoleTetrazolesAngiotensin-Converting Enzyme InhibitorsBlood PressureAngiotensin Receptor AntagonistsDouble-Blind MethodEnalaprilHeart RateInternal medicineInternal MedicinemedicineHumansProdrugsEnalaprilAntihypertensive AgentsAgedAged 80 and overChemotherapybiologybusiness.industryBiphenyl CompoundsAngiotensin-converting enzymeGeneral MedicineMiddle AgedAngiotensin IICandesartanEndocrinologyTherapeutic EquivalencyACE inhibitorHypertensionbiology.proteinCardiologyBenzimidazolesFemaleCardiology and Cardiovascular Medicinebusinessmedicine.drugBlood pressure
researchProduct

Sexual dysfunction in hypertensive patients treated with losartan.

2001

ABSTRACT Background Impaired erectile function in men is a component of the dysmetabolic syndrome of high blood pressure as well as a sequela of antihypertensive therapy. This prospective interventional study in men with uncontrolled hypertension (blood pressure ≥ 140/90 mm Hg) used a survey instrument to assay sexual dysfunction before and after therapy with losartan. Methods We evaluated the influence of a 12-week therapy with losartan in 82 hypertensive subjects with (n = 82) and without (n = 82) a diagnosis of erectile dysfunction using a self-administered questionnaire validated in another 60 subjects with hypertension. Results: From an initial sample of 323 hypertensive men and women,…

AdultMalemedicine.medical_specialtyAngiotensin-Converting Enzyme InhibitorsLosartanInternal medicinemedicineHumansProspective StudiesSexual Dysfunctions PsychologicalProspective cohort studyDiureticsAntihypertensive AgentsAgedbusiness.industrySequelaGeneral MedicineMiddle Agedmedicine.diseaseSurgeryRegimenBlood pressureErectile dysfunctionLosartanSexual dysfunctionHypertensionFemalemedicine.symptombusinessSexual functionmedicine.drugThe American journal of the medical sciences
researchProduct

Factors related to the impact of antihypertensive treatment in antioxidant activities and oxidative stress by-products in human hypertension

2004

The objective was to study factors related to the changes induced by antihypertensive treatment on oxidative status, antioxidant activities, and reactive oxygen species by-products in whole blood and mononuclear peripheral cells. Eighty-nine hypertensive patients (mean age 46 years, 46 men, average 24-h blood pressure 139/88 mm Hg, body mass index 29) were included. After 3 months of nonrandomized allocation to antihypertensive treatment (20 nonpharmacologic, 36 beta-blockers, 33 angiotensin receptor blocker), oxidized/reduced glutathione ratio and malondialdehyde were significantly reduced, and the activity of superoxide dismutase, catalase, and glutathione peroxidase was significantly inc…

AdultMalemedicine.medical_specialtyAntioxidantmedicine.medical_treatmentAngiotensin-Converting Enzyme Inhibitorsmedicine.disease_causeBenzoatesAntioxidantsSuperoxide dismutasechemistry.chemical_compoundInternal medicineInternal MedicinemedicineHumansTelmisartanAntihypertensive AgentsWhole bloodchemistry.chemical_classificationReactive oxygen speciesbiologybusiness.industryGlutathione peroxidaseGlutathioneMiddle AgedMalondialdehydeOxidative StressHydrochlorothiazideTreatment OutcomeEndocrinologyAtenololchemistryHypertensionbiology.proteinBenzimidazolesDrug Therapy CombinationFemalebusinessOxidative stressDNA DamageAmerican Journal of Hypertension
researchProduct

The effects of telmisartan alone or in combination with hydrochlorothiazide on morning home blood pressure control: The SURGE 2 practice-based study

2013

SURGE 2, a large-scale, practice-based study in 10 countries, evaluated the effects of telmisartan alone or with hydrochlorothiazide (HCTZ) on morning (06:00 – 11:59) home blood pressure (HBP) control. Hypertensive patients (clinic blood pressure [BP] 140/90 mmHg) received telmisartan 40 or 80 mg either alone or in combination with HCTZ 12.5 mg for 8 weeks. Treatment could be adjusted if clinic BP remained 140/90 mmHg. Clinic BP was measured in the morning prior to medication, and seated HBP monitoring was performed, three times per day, 2 days per week. A total of 25,882 patients were included (71% were previously using antihypertensives). There was a statistically signifi cant (all p 0.00…

AdultMalemedicine.medical_specialtyEveningAdolescentDiastoleBlood PressureBenzoatesYoung AdultHydrochlorothiazideInternal medicineInternal MedicinemedicineHumansProspective StudiesTelmisartanProspective cohort studyAdverse effectAntihypertensive AgentsMorningAgedAged 80 and overbusiness.industryHome blood pressure monitoring hydrochlorothiazide morning blood pressure control telmisartanGeneral MedicineMED/11 - MALATTIE DELL'APPARATO CARDIOVASCOLAREBlood Pressure Monitoring AmbulatoryMiddle AgedDrug CombinationsEndocrinologyBlood pressureHydrochlorothiazideAnesthesiaHypertensionBenzimidazolesFemaleTelmisartanCardiology and Cardiovascular MedicinebusinessAngiotensin II Type 1 Receptor Blockersmedicine.drug
researchProduct

Effect of dual blockade of renin–angiotensin system on TGFβ1 and left ventricular structure and function in hypertensive patients

2007

The effects of 24 weeks losartan and ramipril treatment, both alone and in combination, on left ventricular mass (LVM), circulating transforming growth factor beta1 (TGFbeta1), procollagen type I (PIP) and III (PIIIP), have been evaluated in hypertensive (HT) patients. A total of 57 HT with stage 1 and 2 essential hypertension were included. After 4 weeks run in, a randomized double-blind, three arms, double dummy, independent trial was used. All HT patients were randomly allocated to three treatment arms consisting of losartan (50 mg/daily), ramipril (5 mg/ daily) and combined (losartan 50 mg/daily + ramipril 5 mg/daily) for 24 weeks. TGFbeta1, PIP and PIIIP, LVM, LVM/h(2.7) and other echo…

AdultMalemedicine.medical_specialtyLeft ventricular structureHeart VentriclesBlood PressureEnzyme-Linked Immunosorbent AssayAngiotensin II Receptor BlockersPeptide hormoneSeverity of Illness IndexDual blockadeCollagen Type ILosartanVentricular Function LeftRenin-Angiotensin SystemTransforming Growth Factor beta1Double-Blind MethodRamiprilInternal medicineRenin–angiotensin systemPrevalenceInternal MedicineHumansMedicineAntihypertensive AgentsUltrasonographyAnalysis of Variancebusiness.industryMiddle AgedAngiotensin IICollagen Type IIITreatment OutcomeEndocrinologyItalyHypertensionACE inhibitorDrug Therapy CombinationFemaleHypertrophy Left VentricularbusinessBiomarkersmedicine.drugJournal of Human Hypertension
researchProduct

Angiotensin II antagonists - an assessment of their acute toxicity.

2013

In Germany, increasing prescription rates of angiotensin II antagonists resulted in rising enquiries to Poisons Information Centres (PICs) during the last decade. Therefore, we aimed to assess their acute toxicity for deriving triage recommendations.An observational case series with data collected retrospectively from eight PICs in Austria, Germany and Switzerland. Inclusion criteria were monoexposure, defined dose, and documented follow-up.In total, 206 cases of exposures to angiotensin II antagonists were included (candesartan, 94; eprosartan, 3; irbesartan, 20; losartan, 26; olmesartan, 16; telmisartan, 18; and valsartan, 29). The median dose expressed as a multiple of their maximum dail…

AdultMalemedicine.medical_specialtyPoison Control CentersTime FactorsPharmacologyToxicologyIrbesartanInternal medicineGermanymedicineHumansAntihypertensive AgentsRetrospective Studiesbusiness.industryPoisoningEprosartanGeneral MedicineMiddle AgedAngiotensin IILosartanValsartanChild PreschoolMedian bodyFemaleTelmisartanDrug OverdoseHypotensionbusinessOlmesartanAngiotensin II Type 1 Receptor Blockersmedicine.drugClinical toxicology (Philadelphia, Pa.)
researchProduct